![The Weekly Break Out Ep. 22: How the US hit Iran, and spooky space moves [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/06/250622_b2_takeoff_USAF-scaled-e1750776866152.jpg?#)
Amgen rolls out phase 3 dosing plan for lead obesity candidate after midstage trial sees high discontinuation, vomiting rates
The company noted high rates of discontinuation due to gastrointestinal events, such as vomiting, in fixed-dose arms of its phase 2 trial.
The company noted high rates of discontinuation due to gastrointestinal events, such as vomiting, in fixed-dose arms of its phase 2 trial.
